Antifungal prophylaxis and pre-emptive therapy.

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

In recent years, several reports have underlined the increasing role of fungal infections as a cause of morbidity and mortality in hospitalized non-haematological patients. For this reason, and also in light of the high mortality rate associated with these infections, chemoprophylaxis has been advocated for surgical patients hospitalized in intensive care units (ICUs). The available evidence suggests that the triazoles fluconazole and itraconazole are able to decrease Candida colonization and possibly infection compared with placebo, but this result has only been obtained in high-risk patients undergoing repeated surgical procedures for tertiary peritonitis. Consequently, triazole antifungal prophylaxis should be used with caution, and only in patients at high risk of invasive candidiasis, including high-risk surgical and ICU patients. A pre-emptive approach, defined as initiating antifungal treatment without confirmation of fungal infection, seems to be effective and safe.

Original languageEnglish
Pages (from-to)75-78
Number of pages4
JournalDrugs
Volume69 Suppl 1
Publication statusPublished - 2009

Fingerprint

Triazoles
Mycoses
Intensive Care Units
Invasive Candidiasis
Therapeutics
Itraconazole
Mortality
Fluconazole
Chemoprevention
Critical Care
Infection
Peritonitis
Candida
Placebos
Morbidity

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Antifungal prophylaxis and pre-emptive therapy. / Viscoli, Claudio.

In: Drugs, Vol. 69 Suppl 1, 2009, p. 75-78.

Research output: Contribution to journalArticle

@article{24b75fe95506437f996ad12ef1827669,
title = "Antifungal prophylaxis and pre-emptive therapy.",
abstract = "In recent years, several reports have underlined the increasing role of fungal infections as a cause of morbidity and mortality in hospitalized non-haematological patients. For this reason, and also in light of the high mortality rate associated with these infections, chemoprophylaxis has been advocated for surgical patients hospitalized in intensive care units (ICUs). The available evidence suggests that the triazoles fluconazole and itraconazole are able to decrease Candida colonization and possibly infection compared with placebo, but this result has only been obtained in high-risk patients undergoing repeated surgical procedures for tertiary peritonitis. Consequently, triazole antifungal prophylaxis should be used with caution, and only in patients at high risk of invasive candidiasis, including high-risk surgical and ICU patients. A pre-emptive approach, defined as initiating antifungal treatment without confirmation of fungal infection, seems to be effective and safe.",
author = "Claudio Viscoli",
year = "2009",
language = "English",
volume = "69 Suppl 1",
pages = "75--78",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",

}

TY - JOUR

T1 - Antifungal prophylaxis and pre-emptive therapy.

AU - Viscoli, Claudio

PY - 2009

Y1 - 2009

N2 - In recent years, several reports have underlined the increasing role of fungal infections as a cause of morbidity and mortality in hospitalized non-haematological patients. For this reason, and also in light of the high mortality rate associated with these infections, chemoprophylaxis has been advocated for surgical patients hospitalized in intensive care units (ICUs). The available evidence suggests that the triazoles fluconazole and itraconazole are able to decrease Candida colonization and possibly infection compared with placebo, but this result has only been obtained in high-risk patients undergoing repeated surgical procedures for tertiary peritonitis. Consequently, triazole antifungal prophylaxis should be used with caution, and only in patients at high risk of invasive candidiasis, including high-risk surgical and ICU patients. A pre-emptive approach, defined as initiating antifungal treatment without confirmation of fungal infection, seems to be effective and safe.

AB - In recent years, several reports have underlined the increasing role of fungal infections as a cause of morbidity and mortality in hospitalized non-haematological patients. For this reason, and also in light of the high mortality rate associated with these infections, chemoprophylaxis has been advocated for surgical patients hospitalized in intensive care units (ICUs). The available evidence suggests that the triazoles fluconazole and itraconazole are able to decrease Candida colonization and possibly infection compared with placebo, but this result has only been obtained in high-risk patients undergoing repeated surgical procedures for tertiary peritonitis. Consequently, triazole antifungal prophylaxis should be used with caution, and only in patients at high risk of invasive candidiasis, including high-risk surgical and ICU patients. A pre-emptive approach, defined as initiating antifungal treatment without confirmation of fungal infection, seems to be effective and safe.

UR - http://www.scopus.com/inward/record.url?scp=75349096073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75349096073&partnerID=8YFLogxK

M3 - Article

VL - 69 Suppl 1

SP - 75

EP - 78

JO - Drugs

JF - Drugs

SN - 0012-6667

ER -